Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_14-cv-03657/USCOURTS-cand-3_14-cv-03657-20/pdf.json

Nature of Suit Code: 830
Nature of Suit: Patent
Cause of Action: 35:145 Patent Infringement

---

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

MLC INTELLECTUAL PROPERTY, LLC,

Plaintiff,

v.

MICRON TECHNOLOGY, INC.,

Defendants.

Case No. 14-cv-03657-SI 

ORDER TO SHOW CAUSE

Re: Dkt. No. 250

On December 7, 2018, the Federal Circuit decided Novartis Pharmaceuticals Corp. v. 

Breckenridge Pharmaceutical Inc., Case No. 2017-2173, ___ F.3d ___ (Fed. Cir. Dec. 7, 2018). 

The Federal Circuit held that a later-filed, earlier-expiring post-URAA patent is not a proper 

obviousness-type double patenting (“OTDP”) reference that can be used to invalidate an earlierfiled, later-expiring pre-URAA patent. Plaintiff contends that this decision renders defendant’s 

OTDP defense moot. Dkt. No. 250.

The Court is inclined to agree with plaintiff that Novartis precludes defendant’s OTDP 

defense, as the two patents upon which defendant relies as invalidating references, the ‘851 and 

‘814 patents, are post-URAA patents that were filed after, and expired before, the pre-URAA ‘571 

patent. Defendant is hereby directed to file a letter no later than December 18, 2018, informing

the Court of its position regarding the viability of its OTDP defense post-Novartis. If defendant 

contends that it may still pursue this defense, the Court will issue a further order regarding what 

further proceedings are necessary to resolve this issue. 

IT IS SO ORDERED.

Dated: December 13, 2018 ______________________________________

SUSAN ILLSTON

United States District Judge

Case 3:14-cv-03657-SI Document 253 Filed 12/13/18 Page 1 of 1